MyoKardia appoints Mark Perry to board
This article was originally published in Scrip
Executive Summary
MyoKardia, a company focused on developing innovative heart disease therapeutics, has appointed Mark Perry to its board of directors. Mr Perry currently serves as chair of the Pathway Therapeutics board and a director of Nvidia Corporation. Between 1994 and 2007 he worked at Gilead Sciences in roles including CFO and executive vice-president of operations.